Search

Displaying results 4951 - 4960 of 10000 in total
  1. Drug

    Cetilistat

    go.drugbank.com/drugs/DB06586
    Investigational

    Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.

  2. Drug

    Bos taurus gallstone

    go.drugbank.com/drugs/DB14248
    Investigational

    Bos taurus gallstone is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Synonyms: Cow-bezoan Cultured in Vitro
  3. Drug

    alpha-Lactalbumin

    go.drugbank.com/drugs/DB15182
    Investigational

    alpha-Lactalbumin is under investigation in clinical trial NCT02082418 (Effects of Alpha-lactalbumin Intake on Metabolic and Cognitive Functions in Elderly).

  4. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. S...

  5. Drug

    Rocakinogene sifuplasmid

    go.drugbank.com/drugs/DB16316
    Investigational

    Rocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma

  6. Drug

    Candida albicans

    go.drugbank.com/drugs/DB10429
    ApprovedInvestigational

    Candida albicans is used in allergenic testing.

  7. Drug

    Saccharomyces cerevisiae

    go.drugbank.com/drugs/DB10447
    Approved

    Saccharomyces cerevisiae is used in allergenic testing.

  8. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

  9. Drug

    Talacotuzumab

    go.drugbank.com/drugs/DB14796
    Investigational

    It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission). … Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123.

  10. Drug

    Sarconeos

    go.drugbank.com/drugs/DB16457
    Investigational

    Sarconeos is an activator of the MAS receptor.